None, D. S. J. & None, D. S. S. (2023). A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre. Journal of Contemporary Clinical Practice, 9(2), 898-911.
MLA
None, Dr. Shailesh Jain and Dr. Sameer Samuel . "A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre." Journal of Contemporary Clinical Practice 9.2 (2023): 898-911.
Chicago
None, Dr. Shailesh Jain and Dr. Sameer Samuel . "A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre." Journal of Contemporary Clinical Practice 9, no. 2 (2023): 898-911.
Harvard
None, D. S. J. and None, D. S. S. (2023) 'A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre' Journal of Contemporary Clinical Practice 9(2), pp. 898-911.
Vancouver
Dr. Shailesh Jain DSJ, Dr. Sameer Samuel DSS. A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre. Journal of Contemporary Clinical Practice. 2023 ;9(2):898-911.
Background: Oral cavity cancer is among the commonest malignancies in India and is closely linked to smokeless and smoked tobacco, areca nut and alcohol use. Most patients present late, and the clinicopathological profile at a given centre guides local prevention, early detection and treatment planning.Aims and objectives: To study the demographic profile, risk factors, clinical presentation, site distribution, histopathological spectrum, stage at presentation and treatment pattern of oral cavity malignancies, and to analyse the association of clinicopathological variables with nodal metastasis and stage at presentation.Materials and methods: A hospital-based observational study was conducted in the Department of Otorhinolaryngology of a tertiary care teaching hospital from June 2022 to May 2023. A total of 120 consecutive patients with histologically confirmed oral cavity malignancy were enrolled. Detailed history, clinical examination, imaging and biopsy were done, and tumours were staged by the AJCC 8th edition. Data were analysed with the chi-square test, and p < 0.05 was considered significant.Results: The mean age was 53.4 ± 12.1 years (range 24-82) with a male to female ratio of 2.3:1; 65.0% of patients were from rural areas. Smokeless tobacco was the commonest habit (65.8%), followed by smoking (40.0%) and alcohol (32.5%); 83.3% had a tobacco habit. Non-healing ulcer (73.3%) and pain (61.7%) were the leading symptoms. The buccal mucosa (31.7%) was the commonest site, followed by the tongue (25.8%) and the gingivobuccal sulcus (16.7%). Squamous cell carcinoma accounted for 93.3% of cases, mostly well (40.0%) or moderately (39.2%) differentiated. A total of 80.8% of patients presented in stage III-IV, and 48.3% had clinically positive neck nodes. Nodal metastasis correlated significantly with higher T stage (p = 0.017) and poorer grade (p = 0.011). Late presentation was significantly associated with symptom duration of three months or more (p = 0.004). Surgery-based multimodality treatment was possible in 68.3%.Conclusion: Oral cavity cancer in this series affected a relatively young, rural, tobacco-exposed population and presented predominantly in advanced stages. Community-level tobacco control, screening for potentially malignant disorders by primary care providers and early referral are essential to shift the stage at diagnosis.
Keywords
Oral cavity cancer
Squamous cell carcinoma
Clinicopathological profile
Smokeless tobacco
Buccal mucosa
Neck node metastasis
Tertiary care centre.
INTRODUCTION
Cancers of the lip and oral cavity represent a major global public health problem. According to GLOBOCAN 2020, about 377,700 new cases and 177,800 deaths from lip and oral cavity cancer occurred worldwide, with the highest rates in South and South-East Asia, Melanesia and parts of Europe [1]. Earlier estimates had already shown that more than half of the global burden is contributed by Asia [2,3]. In India, oral cancer is the commonest cancer among men and one of the three leading cancers among women, accounting for nearly a third of all cancers in the country [4,5]. Analysis of data from 29 population-based cancer registries has confirmed the oral cavity as one of the leading anatomical sites of cancer in India, with the buccal mucosa and tongue being the commonest subsites [6]. The marked regional variation within India, with exceptionally high rates in the central, eastern and north-eastern states, reflects differences in the pattern of tobacco and areca nut use [7].
The aetiology of oral cavity cancer is multifactorial, but tobacco in its various forms is the principal risk factor. In India, the habit of chewing tobacco with or without betel quid and areca nut, along with bidi smoking, is deeply rooted in social practice and is responsible for the majority of cases [8,9]. A systematic review of South Asian studies has shown a significantly raised risk of oral cancer even with betel quid chewing without tobacco, underlining the independent role of areca nut [10]. Alcohol acts synergistically with tobacco, and the combined exposure carries a risk much greater than either habit alone [11,12]. Case-control studies from southern India have shown that chewing, smoking and alcohol each carry a dose-dependent risk, and poor oral hygiene adds further risk [13,14]. Other recognised contributors include chronic mechanical irritation, nutritional deficiency, and oral potentially malignant disorders such as leukoplakia, erythroplakia and oral submucous fibrosis, which carry a variable risk of malignant transformation [15-17].
Despite the fact that the oral cavity is readily accessible to inspection and palpation, a majority of patients in India report to the hospital in advanced stages. Delay arises from patient factors such as ignorance, fear, use of home remedies and poor access to care, as well as from professional factors such as late referral by primary practitioners and dental surgeons [18]. Stage at presentation is the single most important determinant of survival, and the five-year survival drops sharply from early to advanced disease. Staging has recently been refined by the AJCC 8th edition, which has incorporated depth of invasion into T categorisation and extranodal extension into N categorisation for oral cavity cancers [19-21].
Squamous cell carcinoma constitutes over 90% of oral cavity malignancies, and the remainder includes verrucous carcinoma, minor salivary gland tumours and rarer entities [22]. The histological grade, pattern of invasion and perineural and lymphovascular spread are important adverse features that influence the need for adjuvant therapy [23,24]. Understanding these features in the local population is useful because the patterns of presentation vary from one region to another and even among tertiary centres.
The otorhinolaryngologist is often the first specialist to see patients with oral lesions and is closely involved in diagnosis, surgical management and rehabilitation. A systematic documentation of the clinicopathological profile at our centre will help in identifying the high-risk groups, the extent of delay in presentation and the gaps in early detection. This study was therefore undertaken to describe the clinicopathological profile of oral cavity malignancies in a tertiary care centre.
Aims and Objectives
To study the age, sex, residence, occupation and risk factor profile of patients with oral cavity malignancy. To study the clinical presentation, site distribution and stage at presentation. To study the histopathological spectrum, grade and adverse pathological features. To study the treatment pattern and short-term outcome, and to correlate clinicopathological variables with nodal metastasis and stage at presentation.
MATERIALS AND METHODS
Study design, setting and duration
This was a hospital-based, observational study with prospective enrolment, carried out in the Department of Otorhinolaryngology of a tertiary care teaching hospital over a period of 12 months, from June 2022 to May 2023.
Study population and sample size
All consecutive patients with a histopathologically confirmed primary malignancy of the oral cavity who attended the outpatient department or were admitted during the study period and who gave written informed consent were included. A total of 120 patients fulfilled the criteria and constituted the study sample.
Inclusion criteria: (i) patients of either sex aged 18 years or above; (ii) primary malignant tumour arising from the lip (vermilion border excluded from analysis if purely cutaneous), anterior two-thirds of the tongue, buccal mucosa, gingivobuccal sulcus, upper and lower alveolus, retromolar trigone, floor of mouth or hard palate; (iii) histopathological confirmation of malignancy.
Exclusion criteria: (i) recurrent or previously treated malignancy; (ii) tumours of the oropharynx, base of tongue or tonsil; (iii) secondary deposits in the oral cavity from a distant primary; (iv) patients who declined consent or in whom histopathological confirmation was not available.
Data collection
A pre-designed, pre-tested proforma was used. Information was recorded on age, sex, place of residence, occupation, presenting symptoms and their duration, and personal habits, including the type, frequency and duration of smokeless tobacco, areca nut or betel quid use, smoking and alcohol consumption. A history of pre-existing potentially malignant disorder was noted. Delay in presentation was defined as the interval between the onset of the first symptom and the first visit to our department.
A thorough ENT and head and neck examination was done, recording the site, size, extent, appearance, induration, fixity, trismus and mandibular involvement, along with bimanual palpation of the neck for nodal status. Incisional biopsy was taken from the edge of the lesion and fine needle aspiration cytology was done for suspicious nodes. Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) of the face and neck was done for assessment of bone invasion, depth of invasion and nodal disease, and chest radiography or CT thorax and ultrasonography of the abdomen were used to look for distant metastasis.
Staging and histopathology
Tumours were staged according to the AJCC Cancer Staging Manual, 8th edition [19]. Histopathological typing followed the WHO classification, and squamous cell carcinomas were graded as well, moderately or poorly differentiated [22]. In surgical specimens, the depth of invasion, resection margin status (clear ≥ 5 mm, close < 5 mm, involved), perineural invasion (PNI), lymphovascular invasion (LVI), number of nodes involved and extranodal extension (ENE) were recorded.
Treatment and follow-up
Treatment was decided by a multidisciplinary tumour board. Resectable tumours were treated by wide local excision with a 1 cm margin and neck dissection as indicated, with reconstruction where needed. Adjuvant radiotherapy or chemoradiotherapy was advised for patients with adverse pathological features, such as pT3-4 disease, close or involved margins, PNI, LVI, multiple nodes or ENE. Unresectable or medically unfit patients received definitive or palliative chemoradiotherapy or best supportive care. Patients were reviewed monthly for the first six months and then every three months, and the outcome at last follow-up was documented.
Statistical analysis
Data were entered in Microsoft Excel and analysed with SPSS software (version 25). Categorical variables are given as number and percentage, and continuous variables as mean ± standard deviation. The chi-square test was used to test associations, and a p value of < 0.05 was considered statistically significant.
Ethical considerations
The study was approved by the Institutional Ethics Committee, and written informed consent was obtained from all participants. Confidentiality of patient data was maintained throughout.
RESULTS
A total of 120 patients with oral cavity malignancy were included in the study. The mean age of the patients was 53.4 ± 12.1 years (range 24-82 years). The maximum number of patients (31.7%) belonged to the age group of 51-60 years, and 16.7% were aged 40 years or below. There were 84 males (70.0%) and 36 females (30.0%), with a male to female ratio of 2.3:1 (Table 1).
Table 1: Age and sex distribution of patients (n = 120)
Age group (years) Male n Female n Total n (%)
≤ 30 4 2 6 (5.0)
31-40 9 5 14 (11.7)
41-50 21 10 31 (25.8)
51-60 27 11 38 (31.7)
61-70 16 6 22 (18.3)
> 70 7 2 9 (7.5)
Total 84 (70.0%) 36 (30.0%) 120 (100)
Sixty-five percent of the patients were from rural areas. Farmers and manual labourers formed the largest occupational group (43.3%), followed by housewives (22.5%) (Table 2).
Table 2: Residence and occupation of patients (n = 120)
Variable Number (n) Percentage (%)
Residence
Rural 78 65.0
Urban 42 35.0
Occupation
Farmer / manual labourer 52 43.3
Housewife 27 22.5
Business / self-employed 16 13.3
Service / office work 11 9.2
Others (driver, student, retired) 14 11.7
The commonest presenting complaint was a non-healing ulcer (73.3%), followed by pain (61.7%) and a swelling or growth in the mouth (40.8%). Trismus was present in 30.0% and a neck swelling in 28.3% of patients. Weight loss was noted in 25.8% (Table 3). The duration of symptoms was less than three months in 46.7% and six months or more in 21.7% of patients (Table 4).
Table 3: Presenting symptoms (multiple symptoms per patient; n = 120)
Symptom Number (n) Percentage (%)
Non-healing ulcer 88 73.3
Pain 74 61.7
Swelling / growth 49 40.8
Trismus 36 30.0
Neck swelling 34 28.3
Weight loss 31 25.8
Dysphagia / odynophagia 28 23.3
Bleeding from lesion 22 18.3
Altered speech 17 14.2
Loosening of teeth 14 11.7
Table 4: Duration of symptoms before presentation (n = 120)
Duration Number (n) Percentage (%)
< 1 month 9 7.5
1-3 months 47 39.2
> 3-6 months 38 31.7
> 6 months 26 21.7
Total 120 100
Overall, 100 patients (83.3%) had a history of tobacco use in some form. Smokeless tobacco alone was used by 43.3% of patients, smoking alone by 17.5% and both by 22.5%; thus 65.8% used smokeless tobacco and 40.0% smoked. Areca nut or betel quid chewing was reported by 64 patients (53.3%) and alcohol consumption by 39 patients (32.5%). Among the 36 women, 22 (61.1%) used smokeless tobacco, in the form of tobacco-containing betel quid, mishri or tobacco tooth powder. Of the 100 tobacco users, 79% had the habit for more than 10 years (Table 5). A pre-existing potentially malignant disorder was present in 29 patients (24.2%): oral submucous fibrosis in 14, leukoplakia in 11 and erythroplakia in 4.
Table 5: Habit profile of patients (n = 120)
Habit Number (n) Percentage (%)
Tobacco habit (mutually exclusive categories)
Smokeless tobacco only 52 43.3
Smoking only 21 17.5
Both smoking and smokeless 27 22.5
No tobacco habit 20 16.7
Other exposures (not mutually exclusive)
Areca nut / betel quid chewing 64 53.3
Alcohol consumption 39 32.5
Duration of tobacco habit (n = 100)
< 10 years 21 21.0
10-20 years 44 44.0
> 20 years 35 35.0
Pre-existing potentially malignant disorder
Oral submucous fibrosis 14 11.7
Leukoplakia 11 9.2
Erythroplakia 4 3.3
The buccal mucosa was the most frequent site (31.7%), followed by the oral tongue (25.8%), gingivobuccal sulcus (16.7%) and lower alveolus (10.0%) (Table 6, Figure 1). Together, the buccal mucosa and gingivobuccal sulcus accounted for 48.3% of all cases.
Table 6: Site distribution of oral cavity malignancy (n = 120)
Subsite Number (n) Percentage (%)
Buccal mucosa 38 31.7
Tongue (oral part) 31 25.8
Gingivobuccal sulcus 20 16.7
Lower alveolus 12 10.0
Retromolar trigone 7 5.8
Floor of mouth 5 4.2
Hard palate 4 3.3
Upper alveolus 2 1.7
Lip 1 0.8
Total 120 100
On histopathological examination, squamous cell carcinoma was by far the commonest type (93.3%). Of these, 42.9% were well differentiated, 42.0% moderately differentiated and 15.2% poorly differentiated. The non-squamous tumours were verrucous carcinoma (4 cases), adenoid cystic carcinoma (2 cases), mucoepidermoid carcinoma (1 case) and basaloid squamous carcinoma (1 case) (Table 7).
Table 7: Histopathological types and grades of squamous cell carcinoma (n = 120)
Histopathological type Number (n) Percentage (%)
Squamous cell carcinoma (conventional) 112 93.3
Verrucous carcinoma 4 3.3
Adenoid cystic carcinoma 2 1.7
Mucoepidermoid carcinoma 1 0.8
Basaloid squamous carcinoma 1 0.8
Grade of squamous cell carcinoma (n = 112; percentage of SCC)
Well differentiated 48 42.9
Moderately differentiated 47 42.0
Poorly differentiated 17 15.2
Most patients presented with locally advanced primary tumours: 39.2% had T4a and 5.0% T4b disease, whereas only 7.5% had T1 tumours. Clinically positive neck nodes were present in 58 patients (48.3%), including N2 disease in 23.3% and N3 disease in 5.0%. Distant metastasis was present at presentation in 4 patients (3.3%), to the lung in 3 and to bone in 1 (Table 8). On overall staging, 97 patients (80.8%) were in stage III or IV, and only 23 (19.2%) were in stage I or II (Table 9, Figure 2).
Table 8: TNM categories at presentation (AJCC 8th edition; n = 120)
Category Number (n) Percentage (%)
Primary tumour (T)
T1 9 7.5
T2 27 22.5
T3 31 25.8
T4a 47 39.2
T4b 6 5.0
Regional nodes (clinical N)
N0 62 51.7
N1 24 20.0
N2 28 23.3
N3 6 5.0
Distant metastasis (M)
M0 116 96.7
M1 4 3.3
Table 9: Overall clinical stage at presentation (n = 120)
Stage Number (n) Percentage (%)
Stage I 6 5.0
Stage II 17 14.2
Stage III 24 20.0
Stage IVA 59 49.2
Stage IVB 10 8.3
Stage IVC 4 3.3
Total 120 100
Surgery formed part of the treatment in 82 patients (68.3%): surgery alone in 21, surgery with adjuvant radiotherapy in 33 and surgery with adjuvant chemoradiotherapy in 28. Definitive chemoradiotherapy was given to 14 patients (11.7%), and 24 patients (20.0%), mostly with unresectable or metastatic disease or poor general condition, received palliative treatment (Table 10). Among the 82 operated patients, wide local excision with selective neck dissection was the commonest procedure (51.2%), followed by segmental mandibulectomy with modified radical neck dissection (23.2%) (Table 11). Reconstruction was needed in 47 of 82 patients (57.3%), using a pectoralis major myocutaneous flap in 22, a free radial forearm flap in 12, a nasolabial or other local flap in 8 and a split-skin graft in 5.
Table 10: Treatment modality (n = 120)
Treatment Number (n) Percentage (%)
Surgery alone 21 17.5
Surgery + adjuvant radiotherapy 33 27.5
Surgery + adjuvant chemoradiotherapy 28 23.3
Definitive chemoradiotherapy 14 11.7
Palliative treatment / best supportive care 24 20.0
Total 120 100
Table 11: Surgical procedures performed (n = 82)
Procedure Number (n) Percentage (%)
Wide local excision + selective neck dissection (levels I-III/IV) 42 51.2
Segmental mandibulectomy + modified radical neck dissection 19 23.2
Marginal mandibulectomy + selective neck dissection 14 17.1
Partial maxillectomy + neck dissection 5 6.1
Wide local excision alone (T1N0) 2 2.4
Total 82 100
Pathological examination of the specimens showed clear margins in 74.4%, close margins in 17.1% and involved margins in 8.5%. Nodal metastasis was confirmed in 38 of the 82 operated patients (46.3%), with extranodal extension in 17 (20.7%). Perineural invasion was seen in 35.4% and lymphovascular invasion in 17.1% (Table 12). Nodal metastasis was found in 11 of the 52 clinically node-negative operated patients, giving an occult metastasis rate of 21.2%.
Table 12: Histopathological features in surgical specimens (n = 82)
Feature Number (n) Percentage (%)
Resection margin
Clear (≥ 5 mm) 61 74.4
Close (< 5 mm) 14 17.1
Involved 7 8.5
Adverse features
Nodal metastasis (pN+) 38 46.3
Extranodal extension 17 20.7
Perineural invasion 29 35.4
Lymphovascular invasion 14 17.1
When clinical nodal status was correlated with the clinicopathological variables (Table 13), nodal positivity was commonest for tongue primaries (61.3%) and gingivobuccal sulcus tumours (55.0%), but the difference among sites was not statistically significant (p = 0.308). Nodal metastasis increased significantly with advancing T stage, from 11.1% in T1 to 58.5% in T4 tumours (p = 0.017), and with worsening histological grade, from 35.4% in well differentiated to 76.5% in poorly differentiated carcinoma (p = 0.011).
Table 13: Association of clinical nodal status with site, T stage and grade
Variable Total n N+ n (%) Test, p value
Subsite
Tongue 31 19 (61.3)
Buccal mucosa 38 15 (39.5)
Gingivobuccal sulcus 20 11 (55.0)
Alveolus (upper + lower) 14 7 (50.0)
Others 17 6 (35.3) χ² = 4.81, p = 0.308 (NS)
T stage
T1 9 1 (11.1)
T2 27 9 (33.3)
T3 31 17 (54.8)
T4 (4a + 4b) 53 31 (58.5) χ² = 10.14, p = 0.017 (S)
Grade of SCC (n = 112)
Well differentiated 48 17 (35.4)
Moderately differentiated 47 25 (53.2)
Poorly differentiated 17 13 (76.5) χ² = 9.01, p = 0.011 (S)
N+ = clinically node-positive; NS = not significant; S = significant (p < 0.05). 'Others' = retromolar trigone, floor of mouth, hard palate and lip.
Delay in presentation was significantly associated with advanced stage: 90.6% of patients with symptoms for three months or more were in stage III-IV, compared with 69.6% of those who presented earlier (p = 0.004) (Table 14). The pattern of habit also varied by site (Table 15). Smokeless tobacco, alone or with smoking, was used by 79.3% of patients with buccal mucosa or gingivobuccal sulcus cancer, whereas tongue cancer patients more often smoked (48.4%) and had a higher proportion of no tobacco habit (25.8%), although this difference did not reach statistical significance (p = 0.059).
Table 14: Association of duration of symptoms with stage at presentation (n = 120)
Duration of symptoms Stage I-II n (%) Stage III-IV n (%) Total n
< 3 months 17 (30.4) 39 (69.6) 56
≥ 3 months 6 (9.4) 58 (90.6) 64
Total 23 (19.2) 97 (80.8) 120
χ² = 8.49, df = 1, p = 0.004 (significant).
Table 15: Tobacco habit according to subsite (n = 120)
Tobacco habit Tongue (n = 31) Buccal mucosa / GBS (n = 58) Other sites (n = 31) Total (n = 120)
Smokeless only 8 32 12 52
Smoking only 9 5 7 21
Both 6 14 7 27
No tobacco habit 8 7 5 20
GBS = gingivobuccal sulcus. χ² = 12.15, df = 6, p = 0.059 (not significant).
At the last follow-up (median 14 months, range 3-30 months), 52 patients (43.3%) were alive and disease free, 33 (27.5%) were alive with disease, 24 (20.0%) had died and 11 (9.2%) were lost to follow-up. Among the 82 operated patients, locoregional recurrence developed in 14 (17.1%) within a median of 9 months. Early postoperative complications occurred in 25 patients and are listed in Table 16; there was no perioperative mortality.
Table 16: Outcome at last follow-up and postoperative complications
Variable Number (n) Percentage (%)
Status at last follow-up (n = 120)
Alive, disease free 52 43.3
Alive with disease 33 27.5
Dead 24 20.0
Lost to follow-up 11 9.2
Early postoperative complications (n = 82; some patients had more than one)
Surgical site / wound infection 12 14.6
Orocutaneous fistula 6 7.3
Partial flap necrosis 5 6.1
Haematoma / bleeding 2 2.4
DISCUSSION
Oral cavity cancer remains a disease of late presentation in India, and the present study confirms that this holds true even in a tertiary referral setting. The study of 120 patients describes a population that is predominantly male, rural, tobacco exposed and in advanced stage at diagnosis.
The mean age of 53.4 years and the peak incidence in the sixth decade in our study are consistent with Indian reports, in which most patients are in the fifth and sixth decades [25-27]. About one in six patients (16.7%) in our series was 40 years or younger. Oral cancer in the young has been repeatedly described in India, and has been related to the early initiation of tobacco and areca nut chewing, including the use of gutka sachets from adolescence [28,29]. The male to female ratio of 2.3:1 is lower than the ratios of 4:1 or higher reported in older series and is closer to recent estimates, and may reflect the gradual rise in tobacco use among women and the persistent practice of chewing tobacco and mishri among rural women [30]. Women in our series were mostly non-smokers, and 61.1% used smokeless tobacco, which is in line with earlier case-control observations [31].
Two-thirds of our patients came from rural areas, and farmers or manual labourers were the largest occupational group. Similar rural and low-income predominance has been reported from hospital-based studies in northern and southern India [32,33]. These patients usually have limited access to dental and medical services, depend on local healers or pharmacists, and are more likely to continue tobacco use. This also explains the delay in presentation, which has been shown to be influenced by socio-economic factors and health-seeking behaviour [34].
Tobacco use was documented in 83.3% of our patients, and smokeless tobacco was the predominant form (65.8%). This is in agreement with studies from India, in which tobacco chewing alone accounted for the large majority of cases, and with the meta-analysis in which smokeless tobacco was associated with an approximately threefold risk of oral cancer in South Asia [35]. Areca nut chewing was seen in more than half of our patients and is an established carcinogen (Group 1, IARC), and its role in oral submucous fibrosis is well known [36]. Alcohol was consumed by 32.5% of patients, and most of these were also tobacco users, in keeping with the multiplicative interaction described in pooled analyses. The 16.7% of patients without a tobacco habit deserve mention; in them, chronic irritation from sharp teeth or ill-fitting dentures, poor oral hygiene, nutritional deficiency and genetic factors are possible contributors, and a higher proportion of such patients had tongue cancer, as reported earlier [37].
A pre-existing potentially malignant disorder was noted in 24.2% of patients, with submucous fibrosis and leukoplakia being the commonest. This supports the concept that many cancers evolve over years from visible lesions, and it highlights the opportunity for early detection by the primary care physician, the dentist and the ENT surgeon. In the Kerala screening trial, visual screening by trained health workers led to a significant reduction in oral cancer mortality among tobacco and alcohol users, which establishes the value of such an approach in high-risk groups [38].
A non-healing ulcer, pain and a growth were the leading complaints, as reported in most Indian series. The fact that only 7.5% of patients had symptoms of less than one month and that 53.3% had symptoms for more than three months indicates a considerable delay. We found that patients with a delay of three months or more were significantly more likely to present with stage III-IV disease (90.6% versus 69.6%, p = 0.004). The relationship of delay with advanced stage has been documented in Indian and international studies, although some authors have found that the stage depends more on tumour biology and patient factors than on the delay alone [39]. Trismus and bone involvement in many patients also reflect the locally advanced nature of buccal and gingivobuccal tumours, which spread early along the buccinator and into the masticator space and mandible.
In the present study the buccal mucosa (31.7%) was the commonest site, followed by the tongue (25.8%), and the gingivobuccal sulcus (16.7%). This pattern is the characteristic Indian ('gingivobuccal') cancer pattern, which differs from Western series, where the tongue and floor of the mouth predominate, and is attributable to the habit of holding a quid in the buccal sulcus. Studies from Mumbai, central India and Allahabad have also shown the buccal mucosa and the gingivobuccal complex to be the commonest subsites whereas the tongue has predominated in series from some other regions, including Kerala, with higher use of smoking and alcohol. In our series, tongue cancers had a higher proportion of smokers and of patients without a tobacco habit, although this was not statistically significant. The slight increase in the share of the oral tongue is in line with the global observation of a rising incidence of oral tongue cancer, including in young non-smokers[40].
Squamous cell carcinoma comprised 93.3% of the tumours, similar to the 90-95% reported in the studies. Most tumours were well to moderately differentiated (82.1% of SCC), which is the usual finding in tobacco-related oral cancer, and poorly differentiated tumours (15.2%) were associated with a significantly higher rate of nodal metastasis, as in other series [41]. Verrucous carcinoma, which is linked to smokeless tobacco and which has a low metastatic potential, was seen in 3.3%, and minor salivary gland tumours in 2.5%. The adverse features of PNI (35.4%), LVI (17.1%) and ENE (20.7%) in the operated patients are important, since each is an independent predictor of recurrence and survival and is an indication for adjuvant therapy [42,43].
A total of 80.8% of our patients were in stage III-IV at presentation and 39.2% had T4a disease. Such figures, with 60-80% of patients in advanced stage, are typical of Indian tertiary care and cancer centres, which is in contrast with the high proportion of early-stage disease in developed countries [44]. The high proportion of stage IV is partly due to the AJCC 8th edition, in which bone invasion and extensive tumours with moderate to deep invasion are upstaged, and depth of invasion has been shown to be a predictor of nodal metastasis and survival.
Clinically positive neck nodes were present in 48.3% of patients, and an additional 21.2% of clinically node-negative patients who were operated on had occult nodal disease, which supports the need for an elective neck dissection even in the clinically N0 neck. In the randomised trial from Tata Memorial Centre, elective neck dissection gave a significant survival advantage over watchful waiting, which has changed practice in India [45,46]. We found nodal metastasis to be significantly associated with T stage and grade, but not with subsite. Tongue and gingivobuccal lesions had the highest nodal rates, in agreement with the known propensity of oral tongue cancers for early nodal spread, and the occurrence of nodes at levels I-III in the great majority of cases [47,48].
The surgical approach with adjuvant therapy as indicated is the standard of care for resectable oral cavity cancer, and 68.3% of our patients could be treated surgically [46,48]. Adjuvant radiotherapy was given to patients with adverse features, and concurrent cisplatin was added for those with positive margins or extranodal extension, based on the evidence from the EORTC and RTOG trials. A margin of 5 mm or more was achieved in 74.4% of our patients, which is comparable with the figures from large institutional series, and close or involved margins were more likely in tumours of the gingivobuccal sulcus and the retromolar trigone because of the proximity of the mandible [49]. The overall rate of postoperative complications of 30.5% is acceptable in view of the extent of resection and the use of reconstruction in more than half of the patients. Locoregional recurrence in 17.1% of the operated patients at a median of 9 months reiterates that most failures occur early, and that close follow-up for at least two years is important. Short follow-up and loss of 9.2% of patients limit our survival assessment, and long-term survival analysis is required.
The findings emphasise three actions. First, tobacco and areca nut control, including legislation against gutka and pan masala and community-based cessation programmes, remains the most effective primary preventive measure. Second, any oral ulcer, white or red patch or restriction in mouth opening persisting for more than two to three weeks should be investigated by biopsy, and general practitioners, dentists and health workers should be trained to identify and refer such lesions early. Third, ENT surgeons and head and neck teams should adopt a multidisciplinary approach, ensure early elective neck dissection and timely adjuvant therapy, and incorporate rehabilitation, nutrition and counselling in the management.
Limitations of the study
This was a single-centre study with a modest sample size, and the data may not be representative of the community, since referral to a tertiary centre selects patients with more advanced disease. Short follow-up did not permit a reliable survival analysis, and recall bias may have influenced the history of habits and the duration of symptoms. Multicentre studies with longer follow-up and multivariate analysis are needed.
CONCLUSION
Oral cavity malignancy in this tertiary care centre predominantly affected middle-aged, rural men with a long history of smokeless tobacco and areca nut use, although a substantial number of women and young adults were affected. The buccal mucosa and tongue were the commonest subsites, and well and moderately differentiated squamous cell carcinoma was the dominant histology. More than 80% of the patients presented in stage III-IV, nearly half had nodal metastasis, and delay of three months or more was significantly associated with advanced stage. Nodal metastasis correlated with T stage and grade. Reduction in the burden requires effective tobacco and areca nut control, active screening and early biopsy of persistent oral lesions, awareness among primary care providers and timely referral, and a multidisciplinary approach to treatment.
REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
3. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-16.
4. Coelho KR. Challenges of the oral cancer burden in India. J Cancer Epidemiol. 2012;2012:701932.
5. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, et al. Cancer mortality in India: a nationally representative survey. Lancet. 2012;379(9828):1807-16.
6. Sharma S, Satyanarayana L, Asthana S, Shivalingesh KK, Goutham BS, Ramachandra S. Oral cancer statistics in India on the basis of first report of 29 population-based cancer registries. J Oral Maxillofac Pathol. 2018;22(1):18-26.
7. Mishra A, Meherotra R. Head and neck cancer: global burden and regional trends in India. Asian Pac J Cancer Prev. 2014;15(2):537-50.
8. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology. 2003;8(4):419-31.
9. Chaturvedi P, Singh A, Chien CY, Warnakulasuriya S. Tobacco related oral cancer. BMJ. 2019;365:l2142.
10. Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. PLoS One. 2014;9(11):e113385.
11. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99(10):777-89.
12. Petti S. Lifestyle risk factors for oral cancer. Oral Oncol. 2009;45(4-5):340-50.
13. Balaram P, Sridhar H, Rajkumar T, Vaccarella S, Herrero R, Nandakumar A, et al. Oral cancer in southern India: the influence of smoking, drinking, paan-chewing and oral hygiene. Int J Cancer. 2002;98(3):440-5.
14. Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design using incident cancer cases. Oral Oncol. 2008;44(5):446-54.
15. Johnson NW, Jayasekara P, Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000. 2011;57(1):19-37.
16. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52(4):195-215.
17. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, Gonzalez-Moles MA, Kerr AR, et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021;27(8):1862-80.
18. Agarwal AK, Sethi A, Sareen D, Dhingra S. Treatment delay in oral and oropharyngeal cancer in our population: the role of socio-economic factors and health-seeking behaviour. Indian J Otolaryngol Head Neck Surg. 2011;63(2):145-50.
19. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
20. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-37.
21. Ebrahimi A, Gil Z, Amit M, Yen TC, Liao CT, Chaturvedi P, et al. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1138-48.
22. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin: Springer; 1997.
23. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol. 1992;166(4):375-81.
24. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29(2):167-78.
25. Mehrotra R, Singh M, Kumar D, Pandey AN, Gupta RK, Sharma VK. Age specific incidence rate and pathological spectrum of oral cancer in Allahabad. Indian J Med Sci. 2003;57(9):400-4.
26. Khandekar SP, Bagdey PS, Tiwari RR. Oral cancer and some epidemiological factors: a hospital based study. Indian J Community Med. 2006;31(3):157-9.
27. Shenoi R, Devrukhkar V, Chaudhuri B, Sharma BK, Sapre SB, Chikhale A. Demographic and clinical profile of oral squamous cell carcinoma patients: a retrospective study. Indian J Cancer. 2012;49(1):21-6.
28. Iype EM, Pandey M, Mathew A, Thomas G, Sebastian P, Nair MK. Oral cancer among patients under the age of 35 years. J Postgrad Med. 2001;47(3):171-6.
29. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for squamous cell carcinoma of the oral cavity in young people: a comprehensive literature review. Oral Oncol. 2004;40(3):304-13.
30. Krishna Rao SV, Mejia G, Roberts-Thomson K, Logan R. Epidemiology of oral cancer in Asia in the past decade - an update (2000-2012). Asian Pac J Cancer Prev. 2013;14(10):5567-77.
31. Subapriya R, Thangavelu A, Mathavan B, Ramachandran CR, Nagini S. Assessment of risk factors for oral squamous cell carcinoma in Chidambaram, Southern India: a case-control study. Eur J Cancer Prev. 2007;16(3):251-6.
32. Sharma P, Saxena S, Aggarwal P. Trends in the epidemiology of oral squamous cell carcinoma in Western UP: an institutional study. Indian J Dent Res. 2010;21(3):316-9.
33. Thavarool SB, Muttath G, Nayanar S, Duraisamy K, Bhat P, Shringarpure K, et al. Improved survival among oral cancer patients: findings from a retrospective study at a tertiary care cancer centre in rural Kerala, India. World J Surg Oncol. 2019;17(1):15.
34. Kumar S, Heller RF, Pandey U, Tewari V, Bala N, Oanh KT. Delay in presentation of oral cancer: a multifactor analytical study. Natl Med J India. 2001;14(1):13-7.
35. Gangane N, Chawla S, Anshu, Gupta SS, Sharma SM. Reassessment of risk factors for oral cancer. Asian Pac J Cancer Prev. 2007;8(2):243-8.
36. Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132-7.
37. Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther. 2016;12(2):458-63.
38. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365(9475):1927-33.
39. Pitiphat W, Diehl SR, Laskaris G, Cartsos V, Douglass CW, Zavras AI. Factors associated with delay in the diagnosis of oral cancer. J Dent Res. 2002;81(3):192-7.
40. Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008;112(2):345-51.
41. Kademani D, Bell RB, Bagheri S, Holmgren E, Dierks E, Potter B, et al. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. 2005;63(11):1599-605.
42. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-52.
43. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-44.
44. Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. Sens Int. 2020;1:100046.
45. D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521-9.
46. Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am. 2015;24(3):491-508.
47. Noguti J, De Moura CF, De Jesus GP, Da Silva VH, Hossaka TA, Oshima CT, et al. Metastasis from oral cancer: an overview. Cancer Genomics Proteomics. 2012;9(5):329-35.
48. Shah JP, Gil Z. Current concepts in management of oral cancer - surgery. Oral Oncol. 2009;45(4-5):394-401.
49. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009;45(3):201-11.
Recommended Articles
Research Article
Adenoidectomy and Endoscopic Myringotomy with and without ventilation tube insertion for Treatment of Otitis Media with Effusion in 6-12 years old Children.